To evaluate MRF-derived measurements of treatment-induced T1 and T2 changes in prostate cancer patients with metastatic bone disease and compare them with conventional MRI methods, highlighting the significance of this comparison.
Key Findings:
MRF provided faster acquisition times and high repeatability in measuring T1 and T2, which may enhance clinical workflow.
Conventional methods were impractical due to long acquisition times.
MRF-derived measurements showed potential for assessing treatment response in metastatic bone lesions.
Interpretation:
MRF may enhance the assessment of treatment response in metastatic bone disease by providing rapid and reproducible quantitative measurements of T1 and T2, with potential applications in clinical settings.
Limitations:
Small sample size with only 19 participants scanned post-treatment, which may limit the generalizability of the findings.
Limited follow-up time averaging 3.4 months.
Conclusion:
MRF shows promise for integration into clinical protocols for imaging and assessing treatment response in metastatic bone disease, though further validation in larger studies is needed.
by Mihaela Rata, Nina Tunariu, Yun Jiang, Julie Hughes, Georgina Hopkinson, Erica Scurr, Jessica M. Winfield, Vikas Gulani, Dow-Mu Koh, Matthew R. Orton
